404,800 Alkermes plc $ALKS Shares Acquired by Public Sector Pension Investment Board

Public Sector Pension Investment Board grew its position in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 59.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,082,205 shares of the company’s stock after purchasing an additional 404,800 shares during the quarter. Public Sector Pension Investment Board owned about 0.64% of Alkermes worth $43,158,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its holdings in Alkermes by 33.9% in the second quarter. Versant Capital Management Inc now owns 1,445 shares of the company’s stock valued at $76,000 after buying an additional 366 shares during the period. GAMMA Investing LLC boosted its position in Alkermes by 5.7% during the third quarter. GAMMA Investing LLC now owns 7,090 shares of the company’s stock valued at $287,000 after acquiring an additional 385 shares during the last quarter. Abel Hall LLC boosted its position in Alkermes by 5.0% during the third quarter. Abel Hall LLC now owns 8,757 shares of the company’s stock valued at $355,000 after acquiring an additional 417 shares during the last quarter. Allworth Financial LP grew its holdings in Alkermes by 77.4% during the 3rd quarter. Allworth Financial LP now owns 958 shares of the company’s stock worth $39,000 after acquiring an additional 418 shares during the period. Finally, Sequoia Financial Advisors LLC grew its holdings in Alkermes by 4.8% during the 1st quarter. Sequoia Financial Advisors LLC now owns 9,272 shares of the company’s stock worth $328,000 after acquiring an additional 422 shares during the period. Institutional investors own 95.21% of the company’s stock.

Insider Activity

In other news, EVP Craig C. Hopkinson sold 9,000 shares of the company’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $46.99, for a total transaction of $422,910.00. Following the transaction, the executive vice president owned 65,389 shares in the company, valued at approximately $3,072,629.11. This represents a 12.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP David Gaffin sold 2,035 shares of the stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $46.17, for a total transaction of $93,955.95. Following the transaction, the executive vice president directly owned 219,353 shares in the company, valued at $10,127,528.01. This trade represents a 0.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 15,103 shares of company stock worth $697,973 in the last quarter. Company insiders own 4.59% of the company’s stock.

Alkermes Stock Up 3.1%

Alkermes stock opened at $46.85 on Thursday. The company has a quick ratio of 2.02, a current ratio of 2.42 and a debt-to-equity ratio of 0.79. Alkermes plc has a 12-month low of $27.00 and a 12-month high of $55.67. The firm’s fifty day moving average is $43.71 and its 200 day moving average is $41.31. The company has a market capitalization of $7.87 billion, a PE ratio of -2,341.33 and a beta of 0.32.

Alkermes (NASDAQ:ALKS – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.17. The business had revenue of $480.13 million during the quarter, compared to analysts’ expectations of $463.48 million. Alkermes had a negative net margin of 0.02% and a positive return on equity of 0.40%. The business’s quarterly revenue was up 21.8% on a year-over-year basis. During the same period last year, the company posted $0.49 earnings per share. As a group, sell-side analysts predict that Alkermes plc will post -0.52 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Royal Bank Of Canada lifted their price objective on Alkermes from $56.00 to $57.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 4th. Weiss Ratings reissued a “hold (c)” rating on shares of Alkermes in a research note on Wednesday, November 4th. Piper Sandler restated an “overweight” rating and set a $65.00 target price (up from $43.00) on shares of Alkermes in a research report on Tuesday, July 28th. The Goldman Sachs Group initiated coverage on Alkermes in a research report on Thursday, September 24th. They set a “neutral” rating and a $50.00 target price on the stock. Finally, Robert W. Baird set a $61.00 target price on Alkermes in a research note on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.73.

Get Our Latest Stock Report on ALKS

Alkermes Company Profile

(Free Report)

Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for neuroscience-related conditions, including serious mental illness and addiction. Founded in 1987, the company has operations in the United States and Ireland, with its corporate headquarters in Dublin and major U.S. operations in Massachusetts. Its marketed medicines include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and to prevent relapse to opioid dependence after detoxification; Aristada, an injectable treatment for schizophrenia in adults; and Lybalvi, a medicine for schizophrenia and bipolar I disorder in adults.

See Also

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.